Lenvatinib Mesilate is used to treat a certain type of thyroid cancer that has returned or that has spread to other parts of the body and cannot be treated with radioactive iodine.
Lenvatinib Mesilate Capsules Market contains market size and forecasts of Lenvatinib Mesilate Capsules in global, including the following market information:
- Global Lenvatinib Mesilate Capsules Market Revenue, 2017-2022, 2023-2028, ($ millions)
- Global Lenvatinib Mesilate Capsules Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Lenvatinib Mesilate Capsules companies in 2021 (%)
The global Lenvatinib Mesilate Capsules market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
4mg Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Lenvatinib Mesilate Capsules include Eisai, Beacon Pharmaceuticals, Everest Pharmaceuticals, Shilpa Medicare, Qilu Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group, Aosaikang Pharmaceutical, Qingfeng Pharmaceutical Group and Jiangsu Simcere Pharmaceutical, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Lenvatinib Mesilate Capsules manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Lenvatinib Mesilate Capsules Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Lenvatinib Mesilate Capsules Market Segment Percentages, by Type, 2021 (%)
Global Lenvatinib Mesilate Capsules Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Lenvatinib Mesilate Capsules Market Segment Percentages, by Application, 2021 (%)
Global Lenvatinib Mesilate Capsules Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Lenvatinib Mesilate Capsules Market Segment Percentages, By Region and Country, 2021 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Lenvatinib Mesilate Capsules revenues in global market, 2017-2022 (Estimated), ($ millions)
- Key companies Lenvatinib Mesilate Capsules revenues share in global market, 2021 (%)
- Key companies Lenvatinib Mesilate Capsules sales in global market, 2017-2022 (Estimated), (K Units)
- Key companies Lenvatinib Mesilate Capsules sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Eisai
- Beacon Pharmaceuticals
- Everest Pharmaceuticals
- Shilpa Medicare
- Qilu Pharmaceutical
- Chia Tai Tianqing Pharmaceutical Group
- Aosaikang Pharmaceutical
- Qingfeng Pharmaceutical Group
- Jiangsu Simcere Pharmaceutical
- CSPC Pharmaceutical Group
- Sichuan Kelun Pharmaceutical
- Chengdu Brilliant Pharmaceutical
Industry Market Size
